Pipeline

One platform. Two programs. One of them first.

A delivery platform is only worth building if it opens more than one door. Ours opens two, because the same carrier and the same class of payload apply wherever this alarm drives disease. We are nevertheless taking one program first, and taking it properly.

Pipeline. Two preclinical programs and the stage each has reached. Filled stages have published data behind them.
ProgramDiscoveryProof of conceptIND-enablingClinical
01

Rare autoinflammatory syndromes

Lead programHuman blood-cell data in hand

Data publishedData publishedPlannedPlanned
02

Host-directed outbreak response

BiodefencePathogen-agnostic by design

Data publishedPlannedPlannedPlanned
Both programs are preclinical

Program 01

Cryopyrin-associated periodic syndromes

This is the lead asset, and it is the lead for three reasons rather than one.

01

The human data sit here

Our published work used blood from fifteen healthy donors and showed reduced release of the inflammatory signal in nine of them after silencing the sensor. That is the closest thing we have to evidence in a person, and it points at this disease.

02

The need is sharpest here

Patients who respond only partly to current treatment, or who stop responding over time, currently have nowhere upstream to go.

03

The regulatory path is shortest here

These are rare diseases, which brings orphan designation into reach, smaller trials, and a clearer conversation with regulators about what success looks like.

Inflammatory signalling fellNo clear change9 of 15donors respondedA result this strong would arise by chancein roughly one experiment in a hundred.
Fifteen healthy donors, immune cells treated outside the body. Nine responded. (RSC Pharmaceutics 2026)
Our Chief Medical Officer leads the international society for these diseases and treats these patients.
Target selection was made by someone who sees the unmet need in a clinic rather than in a market report.

Program 02

Host-directed outbreak response

In the first weeks of a new outbreak there is no vaccine and no specific antiviral, because identifying a pathogen takes weeks and developing a drug against it takes months. Patients arrive during that gap, and a substantial part of what harms them is their own immune system overreacting.

A therapy aimed at the host rather than at the pathogen does not have to wait. This program would silence the three parts of the alarm panel at once, using several siRNA sequences in a single particle. Because the target is human rather than microbial, the same candidate applies across threat families, and the work involves no live pathogens.

Day one

Patients arrive

Hospitals fill before anyone knows what they face.

Later

The cause is identified

How long this takes cannot be promised in advance.

Later still

A therapy arrives

It must be designed, made and tested before use.

The gap

Much of the harm in this window comes from the patient’s own immune overreaction, not from the cause itself.

A host-directed therapy does not wait to know the cause.

It quiets the body’s own alarm, so one candidate applies broadly and can be given from the first day.